Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Surgery for combined type small cell lung carcinoma

R Hage1, J R Elbers, A Brutel de la Rivière

  • 1Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands.

Thorax
|August 26, 1998
PubMed
Summary

Surgical resection for combined small cell lung cancer (SCLC) shows a 31% five-year survival for stage I, with no survivors in later stages. Surgery may offer a cure for early-stage combined or pure SCLC.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Medical treatments in Leber's hereditary optic neuropathy].

Journal francais d'ophtalmologie·2022
Same author

Impact of lockdown during the COVID-19 outbreak on ophthalmological emergencies in a referral center in France.

Journal francais d'ophtalmologie·2021
Same author

Microcystic macular degeneration in autosomal hereditary optic neuropathies: A cross-sectional retrospective study.

Journal francais d'ophtalmologie·2021
Same author

Giant cell arteritis with ocular involvement successfully treated with tocilizumab and very short-course glucocorticoids: A case report.

Journal francais d'ophtalmologie·2021
Same author

[Delays in the management of ocular complications of giant cell arteritis: A retrospective monocentric study of 33 patients].

La Revue de medecine interne·2020
Same author

Electronic cigarettes and vaping associated pulmonary illness (VAPI): A narrative review.

Pulmonology·2020

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Pulmonary Medicine

Background:

  • Combined type small cell lung cancer (SCLC) is rare, accounting for at most 1% of SCLC cases.
  • These tumors feature a mix of SCLC with squamous cell carcinoma and/or adenocarcinoma components.
  • The study aimed to assess survival outcomes for patients with combined and pure SCLC following surgical resection.

Purpose of the Study:

  • To evaluate the survival rates of patients with combined small cell lung cancer (SCLC) after surgical resection.
  • To compare the survival outcomes of combined SCLC with pure SCLC.
  • To determine the efficacy of surgical resection as a curative treatment for early-stage SCLC.

Main Methods:

  • A retrospective analysis of 2115 patients with bronchogenic carcinoma who underwent pulmonary resection between 1977 and 1994.

Related Experiment Videos

  • Identification of 26 patients with combined SCLC and 74 patients with pure SCLC.
  • Assessment of patient demographics, tumor staging (pTNM), surgical procedures (lobectomy, pneumonectomy, segmentectomy), hospital mortality, and five-year survival rates.

    • Main Results:

    • Combined SCLC patients (n=26) had a mean age of 66.4 years, with squamous cell carcinoma component in 21 cases.
    • Five-year survival for combined SCLC was 31% for stage I, 50% for pT1N0M0, and 25% for pT2N0M0. No stage II or III patients survived five years.
    • Pure SCLC patients (n=74) showed five-year survival of 39% for stage I, 46% for pT1N0M0, and 35% for pT2N0M0. No significant survival difference was observed between combined and pure SCLC in stage I disease.

    Conclusions:

    • Surgical resection for combined SCLC in postoperative stage I offers a 31% cumulative five-year survival.
    • No survivors were observed at five years for combined SCLC patients in postoperative stages II and III.
    • For stage I combined or pure SCLC, surgery can provide a long-term disease-free interval and potentially be curative.